oncnursingnews4 天
Making the Decision: Bispecifics Vs. CAR T-Cell Therapy in Myeloma
Providers should consider lifestyle preferences and other conditions/comorbidities before deciding between bispecific antibodies or CAR T-cell therapy in myeloma. Lifestyle preferences and baseline ...
oncnursingnews4 天
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma
The FDA approved zolbetuximab-clzb plus fluoropyrimidine- and platinum-containing chemotherapy for patients with CLDN18.2-positive locally advanced unresectable or metastatic HER2-negative gastric or ...
oncnursingnews4 天
High-Risk Myeloma Treatment Is Not One-Size-Fits-All
Treatment effectiveness can have different meanings to patients,” a physician assistant said when discussing therapy for high ...
oncnursingnews6 天
Talquetamab May Be Underutilized in Relapsed/Refractory Myeloma
A poll of experts revealed that few are utilizing talquetamab for patients with pretreated relapsed/refractory myeloma.
oncnursingnews8 天
ctDNA Has High Sensitivity ESR1 Mutations in Metastatic Breast Cancer
After a patient with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer experiences disease progression ...
oncnursingnews8 天
Melissa L. Bondy,
Belrestotug/Dostarlimab Improves Responses in PD-L1–High Lung Cancer ...
oncnursingnews11 天
Dawn L. Hershman, MD, MS
Belrestotug/Dostarlimab Improves Responses in PD-L1–High Lung Cancer ...
oncnursingnews11 天
Jayshree Shah, RN, APN-C, MSN, BSN, BS
Nurses, Talk AEs, Interstitial Lung Disease, Before Treating With T-DXd ...
oncnursingnews11 天
SCLC Staging Determines Treatment, Adverse Events
Extensive-stage (stage IV) SCLC, on the other hand, is a disease that has spread outside the bounds of 1 radiation field, and ...